A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients.
Alvarez
R D
RD
Gene Therapy Program, Wallace Tumor Institute, Birmingham, AL 35233-7333, USA.
Curiel
D T
DT
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics / Q000276:immunology*; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D007128:Immunoglobulin Fragments / Q000235:genetics; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D014162:Transfection
D000906:Antibodies; D007128:Immunoglobulin Fragments; D011994:Recombinant Proteins